62613-82-5 | Oxiracetam

Packsize	Purity	Availability	Price	Discounted Price
100mg	97%	in stock	$15.00	$10.00
250mg	97%	in stock	$18.00	$12.00
1g	97%	in stock	$22.00	$15.00
5g	97%	in stock	$40.00	$28.00
25g	97%	in stock	$89.00	$62.00
100g	97%	in stock	$299.00	$209.00

Description

• Catalog Number: AI53930
• Chemical Name: Oxiracetam
• CAS Number: 62613-82-5
• Molecular Formula: C6H10N2O3
• Molecular Weight: 158.1552
• MDL Number: MFCD00242951
• SMILES: NC(=O)CN1CC(CC1=O)O

Computed Properties

• Complexity: 192
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 11
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 2
• Undefined Atom Stereocenter Count: 1
• XLogP3: -2.2

Literature

• Determination of piracetam in rat plasma by LC-MS/MS and its application to pharmacokinetics.

  Biomedical chromatography : BMC 20101001

• Efficacy study of Prunus amygdalus (almond) nuts in scopolamine-induced amnesia in rats.

  Indian journal of pharmacology 20100601

• Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.

  Drugs 20100212

• [Optimization of preparation of poly ( glycidyl methacrylate-divinylbenzene) monolithic column with orthogonal experiments for separation of small molecules].

  Se pu = Chinese journal of chromatography 20100201

• [Evaluation of antihypoxic and antiamnemonic effects of mexicor in animals].

  Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine 20090101

• Oxiracetam pre- but not post-treatment prevented social recognition deficits produced with trimethyltin in rats.

  Behavioural brain research 20050620

• Mild cognitive impairment: animal models.

  Dialogues in clinical neuroscience 20041201

• Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20041115

• Nootropic nefiracetam inhibits proconvulsant action of peripheral-type benzodiazepines in epileptic mutant EL mice.

  Annals of the New York Academy of Sciences 20041001

• Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20040921

• Human models as tools in the development of psychotropic drugs.

  Dialogues in clinical neuroscience 20021201

• Oxiracetam prevented the scopolamine but not the diazepam induced memory deficits in mice.

  Behavioural brain research 20020718

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• Aniracetam improves contextual fear conditioning and increases hippocampal gamma-PKC activation in DBA/2J mice.

  Hippocampus 20020101

• The effects of ascorbic acid and oxiracetam on scopolamine-induced amnesia in a habituation test in aged mice.

  Neurobiology of learning and memory 19950901

• Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.

  Drugs & aging 19940801

• Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.

  Journal of medicinal chemistry 19931224

• Effect of oxiracetam on scopolamine-induced amnesia in the rat in a spatial learning task.

  Pharmacology, biochemistry, and behavior 19921101

• Brain entry and direct central pharmacological effects of the nootropic drug oxiracetam. Oxiracetam: brain entry and pharmacological effects.

  Pharmacopsychiatry 19891001

• Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine.

  Pharmacology, biochemistry, and behavior 19870701